Camp4 Therapeutics Corp

CAMPReported to SECin USCIK 0001736730Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 13. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 13
Form 4 lines at Camp4 Therapeutics Corp, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Gold KellyChief Financial OfficerOpen-market buy$39,60010,000 sharesSep 2, 2026Gold KellyChief Financial Officer$39,600Buy · Sep 2Open-market buy10,000Sep 2, 2026
Schwab Andrew J.—Open-market sell$1,616,000400,000 sharesAug 31, 2026Schwab Andrew J.$1,616,000Sell · Aug 31Open-market sell400,000Aug 31, 2026
Schwab Andrew J.—Open-market sell$4510 sharesAug 26, 2026Schwab Andrew J.$45Sell · Aug 26Open-market sell10Aug 26, 2026
Schwab Andrew J.—Open-market sell$144,08132,018 sharesAug 21, 2026Schwab Andrew J.$144,081Sell · Aug 21Open-market sell32,018Aug 21, 2026
Schwab Andrew J.—Open-market sell$520,738114,700 sharesAug 21, 2026Schwab Andrew J.$520,738Sell · Aug 21Open-market sell114,700Aug 21, 2026